ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

VSTM vs AMPH // GROSS PROFIT MARGIN

Verastem Inc. (NASDAQ) VS. Amphastar Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: VSTM 2 — AMPH 7
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VSTM VS. AMPH) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC VSTM AMPH SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin ACTIVE — 49.50% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 9.00% -44.00 AMPH /roic <GO>
EV/EBITDA & P/E Valuation — 9.4x — TIE /valuation <GO>
Free Cash Flow Yield -11.72% 10.58% -22.30 AMPH /fcf-yield <GO>
Operating Margin -60.00% 19.50% -79.50 AMPH /operating-margins <GO>
Net Profit Margin -60.00% 13.60% -73.60 AMPH /net-margins <GO>
Revenue Growth (YoY) 180.00% -1.70% +181.70 VSTM /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 2.47 -2.27 AMPH /balance-sheet <GO>
Piotroski F-Score Quality 3/9 7/9 -4.00 AMPH /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 61.2 63.6 -2.40 AMPH /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 10.9x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.18B $1.18B $4.7M VSTM /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR VSTM REV AMPH REV VSTM GROSS % AMPH GROSS % VSTM FCF AMPH FCF
FY 2025 $30.9M $719.9M — 49.5% -$137.5M $121.2M
FY 2024 $10.0M $732.0M — 51.1% -$104.8M $172.3M
FY 2023 $257.8M $644.4M — — -$86.5M $183.5M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VSTM // BETA —
AMPH // BETA —